Impact of Triazole Therapeutic Drug Monitoring Availability and Timing | Zendy

Erin K McCreary | Zendy; Meg L. Bayless | Zendy; Ahn P. Van | Zendy; Alexander J. Lepak | Zendy; Donald A. Wiebe | Zendy; Lucas Schulz | Zendy; David R. Andes | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of Triazole Therapeutic Drug Monitoring Availability and Timing

Author(s) -

Erin K McCreary,

Meg L. Bayless,

Ahn P. Van,

Alexander J. Lepak,

Donald A. Wiebe,

Lucas Schulz,

David R. Andes

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01245-19

Subject(s) - therapeutic drug monitoring , medicine , drug , antifungal , triazole , serum concentration , pharmacology , therapeutic effect , intensive care medicine , chemistry , organic chemistry , dermatology

Therapeutic drug monitoring (TDM) is an established strategy to optimize antifungal therapy with certain triazoles. While established relationships exist between concentration and safety or efficacy, the impact of TDM timing on outcomes is unknown. We report clinical outcomes, including antifungal exposure and mortality, in patients receiving institutional versus reference laboratory TDM.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research